Dental Tribune International

Vivos Therapeutics raises consumer awareness of its sleep apnea treatment

DENVER, U.S./‎WILKES-BARRE, Pa., U.S.: Vivos Therapeutics, an American company that seeks to find the best evidence-based treatment for obstructive sleep apnea (OSA), has recently collaborated with one of the nation’s largest dental product and equipment distributors, Benco Dental, to promote the Vivos System apnea treatment in the U.S. and expand the company’s client base. As part of the partnership, Benco will offer its customers a unique in-person opportunity to obtain more information on the treatment and to find out how it benefits sleep apnea sufferers and dental practitioners in a series of events that will take place from October this year.

Sleep disorders, including sleep apnea, are a major health issue in the U.S. According to the American Sleep Apnea Association, approximately 22 million Americans suffer from sleep apnea and 80% of OSA cases are undiagnosed. “Sleep apnea is a serious and growing health epidemic facing America,” said Kirk Huntsman, CEO at Vivos. “Our newly formed partnership with Benco Dental will allow our revolutionary technology to reach dentists and their patients throughout the U.S. and introduce them to our VIP program designed specially to help clinicians achieve success, regardless of their experience levels in sleep dentistry.”

The Vivos System uses a proprietary variety of oral appliances to restore and reopen the upper airway without the patient having to undergo surgery. The procedure is completely noninvasive and does not require the patient to take any pharmaceutical drugs. At the beginning of the treatment, the patient is prescribed a custom-made oral appliance and is asked to wear it at night while sleeping. Patients can start seeing the results after 18 months of continued use.

“Our company has a long history of bringing to market innovative products from trailblazing companies,” said Chuck Cohen, Managing Director at Benco Dental. “The Vivos System stands as one of those potential game changers because it’s a possible curative solution—a technology-enabled, multidisciplinary, comprehensive solution—that dentists are uniquely qualified to apply. The Vivos vision of empowering clinicians to rid the world of OSA is keenly aligned with Benco’s own commitment to driving dentistry forward and opening new worlds of treatment possibilities,” he concluded.

More information about the treatment can be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2019 - All rights reserved - Dental Tribune International